Midatech Pharma
Market Cap
UK£17.0m
Last Updated
2020/10/30 20:48 UTC
Data Sources
Company Financials
Executive Summary
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. More Details
Snowflake Analysis
Adequate balance sheet and overvalued.
Similar Companies
Share Price & News
How has Midatech Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MTPH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-8.5%
MTPH
-1.7%
GB Biotechs
-5.1%
GB Market
1 Year Return
-66.7%
MTPH
41.2%
GB Biotechs
-20.0%
GB Market
Return vs Industry: MTPH underperformed the UK Biotechs industry which returned 45.1% over the past year.
Return vs Market: MTPH underperformed the UK Market which returned -19.3% over the past year.
Shareholder returns
| MTPH | Industry | Market | |
|---|---|---|---|
| 7 Day | -8.5% | -1.7% | -5.1% |
| 30 Day | -8.5% | 7.1% | -4.3% |
| 90 Day | -19.4% | 7.1% | -4.5% |
| 1 Year | -66.7%-66.7% | 42.3%41.2% | -17.0%-20.0% |
| 3 Year | -97.3%-97.3% | 5.7%4.1% | -13.6%-24.3% |
| 5 Year | -99.5%-99.5% | 36.0%33.1% | 10.2%-14.6% |
Price Volatility Vs. Market
How volatile is Midatech Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
Don't Ignore The Fact That This Insider Just Sold Some Shares In Midatech Pharma plc (LON:MTPH)4 months ago | Simply Wall St
What Kind Of Shareholder Appears On The Midatech Pharma plc's (LON:MTPH) Shareholder Register?8 months ago | Simply Wall St
Did Changing Sentiment Drive Midatech Pharma's (LON:MTPH) Share Price Down A Disastrous 99%?Valuation
Is Midatech Pharma undervalued compared to its fair value and its price relative to the market?
2.33x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MTPH is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: MTPH is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTPH is good value based on its PB Ratio (2.3x) compared to the GB Biotechs industry average (6.2x).
Next Steps
Future Growth
How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Midatech Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Midatech Pharma's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Midatech Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Midatech Pharma performed over the past 5 years?
-3.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTPH is currently unprofitable.
Growing Profit Margin: MTPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).
Return on Equity
High ROE: MTPH has a negative Return on Equity (-486.89%), as it is currently unprofitable.
Next Steps
Financial Health
How is Midatech Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: MTPH's short term assets (£10.3M) exceed its short term liabilities (£7.3M).
Long Term Liabilities: MTPH's short term assets (£10.3M) exceed its long term liabilities (£107.0K).
Debt to Equity History and Analysis
Debt Level: MTPH's debt to equity ratio (70.2%) is considered high.
Reducing Debt: MTPH's debt to equity ratio has increased from 4.2% to 70.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTPH has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: MTPH is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
Next Steps
Dividend
What is Midatech Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.6yrs
Average management tenure
CEO
Stephen Stamp (58 yo)
0.58
Tenure
UK£206,852
Compensation
Mr. Stephen A. Stamp serves as Chief Financial Officer and Director of Midatech Pharma plc since September 9, 2019. He serves as Chief Executive Officer at Midatech Pharma plc since March 31, 2020. He serv ...
CEO Compensation Analysis
Compensation vs Market: Stephen's total compensation ($USD267.99K) is about average for companies of similar size in the UK market ($USD349.56K).
Compensation vs Earnings: Insufficient data to compare Stephen's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 0.58yr | UK£206.85k | 0.079% £ 13.5k | |
| Chief Business Officer | no data | no data | no data | |
| Head of Manufacturing | no data | no data | no data | |
| Executive Vice President of Research & Development | 2.58yrs | no data | 0.0032% £ 539.8 | |
| President of Midatech Pharma US Inc | 4.75yrs | no data | no data |
2.6yrs
Average Tenure
58yo
Average Age
Experienced Management: MTPH's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 0.58yr | UK£206.85k | 0.079% £ 13.5k | |
| Senior Independent Non-Executive Director | 5.83yrs | UK£30.40k | 0.081% £ 13.9k | |
| Independent Non-Executive Chairman | 6.58yrs | UK£90.00k | 0.039% £ 6.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 16yrs | UK£30.40k | 0.035% £ 5.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.2yrs
Average Tenure
61yo
Average Age
Experienced Board: MTPH's board of directors are considered experienced (6.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 168.5%.
Top Shareholders
Company Information
Midatech Pharma plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Midatech Pharma plc
- Ticker: MTPH
- Exchange: AIM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£17.030m
- Shares outstanding: 63.07m
- Website: https://www.midatechpharma.com
Number of Employees
Location
- Midatech Pharma plc
- Oddfellows House
- 19 Newport Road
- Cardiff
- South Glamorgan
- CF24 0AA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MTPH | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Dec 2014 |
| 5MPA | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2014 |
| MTP | NasdaqCM (Nasdaq Capital Market) | SPON ADS EACH REP 5 ORD SHS(R/S) | US | USD | Dec 2015 | |
| 5MPA | BST (Boerse-Stuttgart) | SPON ADS EACH REP 5 ORD SHS(R/S) | DE | EUR | Dec 2015 | |
| 5MPD | DB (Deutsche Boerse AG) | SPON ADS EACH REP 5 ORD SHS(R/S) | DE | EUR | Dec 2015 |
Biography
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/30 20:48 |
| End of Day Share Price | 2020/10/30 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.